Detailed analysis of the new forces driving growth in the worldwide oncology market. Overview of the cost pressures on healthcare systems and growing recourse to health technology assessment that are complicating market entry for new cancer drugs. Analysis of NICE decisions on premium-priced oncology products, the wider political context in which these decisions are taken, and what they could mean for oncology players in other markets. Detailed exploration of how a multi-faceted value proposition needs to be constructed for new cancer therapies, including survival benefits, cost-effectiveness and more personal components such as quality of life.

Use this report to

Detailed understanding of the new growth drivers in the world oncology market and the emerging threats to continued growth Insight into how healthcare systems are evolving in their efforts to manage cost inflation and how these changes present significant challenges to oncology market growth. Compare approaches to health technology assessment in key markets such as the UK and the US; understand how these raise the bar to entry for new oncology products. Detailed insight into the different components of value that will enable new cancer therapies to carve out niches in the new payer-dominated environment.

Discover

What will be the market trend for oncology products in the years to 2012 and beyond? How has the treatment paradigm for oncology changed in terms of targeted therapies, niche indications and payer influence? What are governments, HTA agencies, health insurers and other influencers/payers in key markets such as the UK and the US doing to address budgetary pressure from pharmaceuticals in general and new oncology products in particular?

Source: Business Insights